Twice-Yearly Lenacapavir Could Support HIV Prevention in Vulnerable Populations
Lenacapavir, a twice yearly injection, may be a promising alternative to the current standard of care for HIV prevention, according to the results of a randomized clinical trial published in the New England Journal of Medicine.
Lenacapavir, a twice yearly injection, may be a promising alternative to the current standard of care for HIV prevention, according to the results of a randomized clinical trial published in the New England Journal of Medicine.
